Jazz Patent Suit Over Xyrem Survives Dismissal In NJ
By Adam Lidgett · July 8, 2026, 9:23 PM EDT
A New Jersey federal judge has refused to let generic-drug company Tris Pharma Inc. escape a suit claiming its attempt to sell a competing version of Jazz Pharmaceuticals' narcolepsy drug Xyrem...
To view the full article, register now.